The assay is indicated as the first and only analytically and clinically validated, FDA and CE IVD-approved IHC companion diagnostic for determining FRα protein expression to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who may be eligible for treatment with ELAHERE (mirvetuximab soravtansine) [14,20,21,22,23]. Here, FOLR1 is linked to peritoneum cancer.